FDA Approves KLYGEFA for Generalized Myasthenia Gravis
The first dual-binding nanobody C5 inhibitor is now approved as a once-weekly self-administered treatment for the chronic autoimmune muscle disorder.
Updated on Nov. 16, 2026 in Asthma

The U.S. Food and Drug Administration approved KLYGEFA (gefurulimab-gaks), developed by Alexion, AstraZeneca Rare Disease, for generalized myasthenia gravis, a chronic autoimmune disorder that causes muscle weakness. The approval was announced November 16, 2026.
Why it matters
KLYGEFA adds a new option for people living with generalized myasthenia gravis, a condition that affects roughly 37 people per 100,000 in the United States. Phase III PREVAIL trial data showed improvement compared with placebo, offering patients a treatment that can be given at home.
The Phase III PREVAIL trial measured improvement in MG-ADL score from baseline at week 26 against placebo, with clinically meaningful gains appearing as early as week one. Real-world outcomes in routine practice remain to be seen.
The players
Alexion, AstraZeneca Rare Disease
Alexion, AstraZeneca Rare Disease is the rare disease business unit of AstraZeneca that develops treatments for serious conditions, including neuromuscular disorders.
Muscular Dystrophy Association (MDA)
The Muscular Dystrophy Association is a U.S. nonprofit that funds neuromuscular disease research and provides care and advocacy services for people with conditions such as myasthenia gravis.
The details
KLYGEFA is administered as a once-weekly subcutaneous autoinjector that patients can use themselves. It works by targeting key pathways involved in the immune system's attack on the neuromuscular junction.
Timeline
November 16, 2026: FDA approval of KLYGEFA announced.
December 8, 2026: Alexion, AstraZeneca Rare Disease holds an Industry Update Webinar on KLYGEFA for families and clinicians.
Health Landscape
KLYGEFA extends the C5 inhibitor class of complement-blocking therapies into a once-weekly, self-administered format for generalized myasthenia gravis. The approval adds a home-administered option to a treatment category that has largely required clinic-based infusions.
KLYGEFA is given as a once-weekly self-administered autoinjector, which may reduce the need for frequent clinic visits. Patients and caregivers should discuss with their clinicians whether this option fits their treatment plan.
The takeaway
Patients with generalized myasthenia gravis now have a once-weekly, home-administered option to discuss with their doctors. Asking a clinician how a new treatment fits individual symptoms and care goals is a practical first step.
What happens next
Alexion, AstraZeneca Rare Disease has scheduled an Industry Update Webinar on KLYGEFA for December 8, 2026.
Further reading
Explore more on Asthma for related respiratory and immune-system coverage.






